Affymetrix Launches GeneChip-compatible(TM) Applications Program; Program Underscores Company's Commitment to Supporting Customers with Integrated Microarray Solutions.

SANTA CLARA, Calif. -- Affymetrix Inc. (Nasdaq:AFFX) today announced the launch of its GeneChip-compatible(TM) Applications Program, providing customers with a broad spectrum of software solutions for biomedical research and development seamlessly integrated with the GeneChip(R) platform. Under this program, leading software developers are collaborating with Affymetrix to deliver software solutions which apply gene expression and genetic variation data to translational medicine, discovery research and systems biology. E[acute accent]"When customers see the GeneChip-compatible logo with participating software applications, they will know that the GeneChip-compatible application provides a unified workflow and direct data exchange with the Affymetrix GeneChip platform," said Mike Lelivelt, senior manager of the GeneChip-compatible Applications Program at Affymetrix. "These software providers are working with us to establish key standards in the marketplace and to maintain compatibility as the GeneChip technology evolves." E[acute accent]Nineteen leading software providers have already joined the GeneChip-compatible Applications Program. They include Biocomputing Platforms, BioDiscovery, Biotique Systems, Genedata, GeneGo, Gene-IT, Genomatix Software, Golden Helix, IMC, Ingenuity Systems, Insightful, Ocimum Biosolutions, Partek, Progeny Software, Rosetta Biosoftware, Strand Life Sciences, Stratagene, Teneo Sciences, and VizX Labs. E[acute accent]"The tight integration of the GeneChip-compatible software applications with our core GeneChip platform provides customers with the most effective and innovative solutions tailored to their individual needs," said Steve Lincoln, vice president of Informatics at Affymetrix. "Together with these leading software providers, we will continue to expand upon the many proven uses of the Affymetrix GeneChip platform in both basic research and applied biomedical R&D." E[acute accent]To find more information on the software providers in Affymetrix' GeneChip-compatible Applications Program, and to access the company's new web-based software solutions catalog, please visit www.affymetrix.com/genechip/compatible. E[acute accent]The GeneChip-compatible Applications Program is an extension of the Affymetrix Developers Network (ADN), a forum through which Affymetrix actively supports its ADN participants and customers. ADN is one of the largest third-party software developer communities within the life science industry, and membership is free-of-charge for both commercial and academic software developers. For more information on both the ADN and GeneChip-compatible Applications Programs, please visit www.affymetrix.com/genechip/developer.

E[acute accent]About Affymetrix:

E[acute accent]Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,200 GeneChip systems have been shipped around the world and more than 3,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyze the relationship between genetics and health. Headquartered in Santa Clara, Calif., Affymetrix has subsidiaries in Europe and Asia in addition to manufacturing facilities in Sacramento, Calif. and Bedford, Mass. The company has about 900 employees worldwide. For more information about Affymetrix, please visit the company's website at www.Affymetrix.com.

E[acute accent]All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, uncertainties relating to technological approaches, manufacturing, product development (including uncertainties relating to the success of the GeneChip-compatible Applications Program discussed in this press release), personnel retention, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2004 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

E[acute accent]NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.